The rationale for combining anti-angiogenics with immunotherapy is based on the immunosuppressive properties of VEGF, which has been shown to decrease T cell recruitment and infiltration into the tumor [18], reduce adhesion of immune effector cells to tumor vessels [172], hampers T cell function [173], affects the functional capacity of dendritic cells [174] and enables the accumulation of Tregs [175]. The gene discussed is VEGFA; the disease is neoplasm.